Equities Analysts Issue Forecasts for Omeros FY2026 Earnings

Omeros Corporation (NASDAQ:OMER) – Equities researchers at HC Wainwright dropped their FY2026 earnings per share estimates for Omeros in a report released on Thursday, January 8th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings of ($2.30) per share for the year, down from their previous estimate of ($1.77). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for Omeros’ FY2027 earnings at ($0.51) EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $5.13 EPS.

Other equities analysts have also issued research reports about the stock. D. Boral Capital reiterated a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Thursday, January 8th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. WBB Securities restated a “strong-buy” rating and issued a $45.00 target price on shares of Omeros in a research report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Omeros Stock Performance

Shares of OMER opened at $12.62 on Monday. The firm has a market capitalization of $894.76 million, a price-to-earnings ratio of -6.25 and a beta of 2.38. Omeros has a one year low of $2.95 and a one year high of $17.65. The stock’s fifty day moving average is $10.81 and its 200-day moving average is $6.82.

Omeros (NASDAQ:OMER) last announced its earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.39.

Institutional Investors Weigh In On Omeros

Several hedge funds have recently bought and sold shares of OMER. Wealth Enhancement Advisory Services LLC raised its holdings in Omeros by 9.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 31,728 shares of the biopharmaceutical company’s stock worth $545,000 after purchasing an additional 2,631 shares during the period. Harbour Investments Inc. raised its stake in Omeros by 46.1% during the 2nd quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 4,251 shares during the period. Russell Investments Group Ltd. lifted its holdings in Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 5,677 shares in the last quarter. Rhumbline Advisers grew its stake in Omeros by 7.1% in the third quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 7,048 shares during the period. Finally, Cypress Capital Group increased its holdings in shares of Omeros by 20.7% in the second quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 7,200 shares in the last quarter. 48.79% of the stock is owned by hedge funds and other institutional investors.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.